


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1     **Claim 1.**       (Currently amended) A compound having the formula:



2

3     wherein

4         R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are members independently selected from H, substituted or  
5                 unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or  
6                 unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or  
7                 unsubstituted heteroaryl, OR<sup>8</sup>, NO<sub>2</sub>, CN and halogen

8     wherein

9         R<sup>8</sup> is a member selected from H, substituted or unsubstituted alkyl,  
10                 substituted or unsubstituted cycloalkyl and substituted or  
11                 unsubstituted aryl;

12         R<sup>5</sup> is a member selected from H, substituted or unsubstituted alkyl, substituted or  
13                 unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl,  
14                 substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl,  
15                 CN and C(O)R<sup>9</sup>

16     wherein

17         R<sup>9</sup> is a member selected from H, substituted or unsubstituted alkyl,  
18                 substituted or unsubstituted cycloalkyl, substituted or unsubstituted  
19                 heteroalkyl, NR<sup>10</sup>R<sup>11</sup> and OR<sup>11</sup>

20     wherein

R<sup>10</sup> is a member selected from H, substituted or unsubstituted  
alkyl, substituted or unsubstituted cycloalkyl and OR<sup>12</sup>

wherein

R<sup>12</sup> is a member selected from H, substituted or  
unsubstituted alkyl, substituted or unsubstituted  
cycloalkyl and substituted or unsubstituted  
heteroalkyl;

R<sup>11</sup> is a member selected from H, C(O)R<sup>13</sup>, substituted or  
unsubstituted alkyl, substituted or unsubstituted cycloalkyl,  
substituted or unsubstituted heteroalkyl, substituted or  
unsubstituted heterocycloalkyl, and substituted or  
unsubstituted aryl, and wherein R<sup>10</sup> and R<sup>11</sup>, together with  
the nitrogen to which they are bound, are optionally joined  
to form a substituted or unsubstituted heterocycloalkyl ring  
system having from 3 to 7 members

wherein

R<sup>13</sup> is a member selected from H, substituted or  
unsubstituted alkyl, substituted or unsubstituted  
cycloalkyl, substituted or unsubstituted heteroalkyl  
and NR<sup>14</sup>R<sup>15</sup>

wherein

R<sup>14</sup> and R<sup>15</sup> are members independently selected  
from H, substituted or unsubstituted alkyl  
and substituted or unsubstituted heteroalkyl;

R<sup>6</sup> is a member selected from H, ~~substituted or unsubstituted alkyl~~, substituted  
alkyl, substituted and unsubstituted heteroalkyl, CN, substituted or  
unsubstituted aryl, substituted or unsubstituted heteroaryl and C(O)R<sup>16</sup>

wherein



R<sup>16</sup> is a member selected from substituted or unsubstituted alkyl,  
substituted or unsubstituted heteroalkyl, substituted or

51 unsubstituted aryl, substituted or unsubstituted heteroaryl,  $\text{NR}^{17}\text{R}^{18}$   
52 and  $\text{OR}^{17}$   
53 wherein  
54  $\text{R}^{17}$  and  $\text{R}^{18}$  are members independently selected from H,  
55 substituted or unsubstituted alkyl, substituted or  
56 unsubstituted heteroalkyl and substituted or unsubstituted  
57 aryl, and wherein  $\text{R}^{10}$  and  $\text{R}^{11}$ , together with the nitrogen to  
58 which they are bound, are optionally joined to form a  
59 heterocycloalkyl ring system having from 3 to 7 members;  
60  $\text{R}^7$  is a member selected from H, substituted or unsubstituted alkyl and substituted  
61 or unsubstituted heteroalkyl; ~~and~~  
62 ~~n is an integer from 1 to 4.~~

1 **Claim 2.** (Previously presented) The compound according to claim 1, wherein at  
2 least one of  $\text{R}^{10}$  and  $\text{R}^{11}$  is substituted or unsubstituted  $\text{C}_1\text{-C}_6$  alkyl.

1 **Claim 3.** (Previously presented) The compound according to claim 1, wherein  $\text{R}^5$  is  
2 a member selected from substituted or unsubstituted  $\text{C}_1\text{-C}_6$  alkyl, substituted or  
3 unsubstituted  $\text{C}_1\text{-C}_6$  heteroalkyl, substituted or unsubstituted  $\text{C}_1\text{-C}_6$  cycloalkyl and  
4 substituted or unsubstituted  $\text{C}_1\text{-C}_6$  heterocycloalkyl.

1 **Claim 4.** (Currently amended) The compound according to claim 1, having the  
2 formula:



3  
4 wherein

5 ~~n is 1 or 2.~~

1 **Claim 5.** (Cancelled)

1   **Claim 6.**       (Currently amended) The compound according to claim ~~[[5]]~~ 4, wherein  
2   R<sup>5</sup> is selected from substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl and substituted or  
3   unsubstituted C<sub>1</sub>-C<sub>6</sub> cycloalkyl.

1   **Claim 7.**       (Previously presented) The compound according to claim 4, wherein R<sup>3</sup> is  
2   halogen.

1   **Claim 8.**       (Previously presented) A pharmaceutical formulation comprising a  
2   compound according to claim 1 and a pharmaceutically acceptable carrier.

1   **Claim 9.**       (Withdrawn) A method of inhibiting HIV in a cell, said method  
2   comprising contacting said cell with an amount of a compound according to claim 1  
3   sufficient to inhibit said HIV.

1   **Claim 10.**      (Withdrawn) The method according to claim 9, wherein said HIV is a  
2   drug resistant mutant.

1   **Claim 11.**      (Withdrawn) A method of inhibiting reverse transcriptase in a cell, said  
2   method comprising contacting said cell with an amount of a compound according to  
3   claim 1 sufficient to inhibit said reverse transcriptase.

1   **Claim 12.**      (Withdrawn) The method according to claim 9, wherein said cell is in a  
2   human.

1   **Claim 13.**      (Withdrawn) The method according to claim 10, wherein said cell is in a  
2   human.

1   **Claim 14.**      (Withdrawn) A method of treating HIV infection in a human subject  
2   comprising administering to said subject an amount of a compound according to claim 1,  
3   sufficient to treat said HIV infection.

1   **Claim 15.**      (Withdrawn) The method according to claim 14, wherein said HIV is a  
2   drug resistant mutant.

1   **Claim 16.**     (Withdrawn) A method of providing prophylaxis against HIV infection  
2   comprising administering a prophylactic amount of a compound according to claim 1 to a  
3   person who is at risk of HIV infection.

1   **Claim 17.**     (Withdrawn) The method according to claim 13, wherein said HIV is a  
2   drug resistant mutant.

1   **Claim 18.**     (New) The compound according to claim 1, wherein R<sup>6</sup> is a member  
2   selected from substituted and unsubstituted ether, substituted and unsubstituted polyether,  
3   -CH<sub>2</sub>OH, and -CH<sub>2</sub>OC(O)CH<sub>3</sub>.